A Primer on Arrhythmias in Patients with Hypertrophic Cardiomyopathy

Overview

Journal Curr Cardiol Rep

Publisher Current Science

Specialty Cardiology & Vascular Diseases

Date 2012 Jul 25

PMID 22825919

Citations 6

Authors

Katy E Bockstall

Mark S Link

Affiliations

Soon will be listed here.

Abstract

Patients with hypertrophic cardiomyopathy are at risk of atrial and ventricular arrhythmias, yet treatment options for these patients are made almost solely by extrapolation from patients with other diseases. Heart block may be seen spontaneously but is especially prevalent following septal reduction strategies. Atrial fibrillation is the most common arrhythmia in patients with hypertrophic cardiomyopathy. The onset of atrial fibrillation often represents a turning point clinically for patients, marked by substantial functional deterioration and morbidity. Sudden cardiac death is the most common cause of death in the young patient, but still contributes to mortality in older patients. Major risk factors for sudden cardiac death include resuscitated sudden cardiac death, marked hypertrophy, syncope, and family history of sudden cardiac death due to hypertrophic cardiomyopathy. Minor risk factors for sudden cardiac death include nonsustained ventricular tachycardia, and hypotensive response to exercise. Emerging possible risk factors include atrial fibrillation, myocardial ischemia, left ventricular outflow tract obstruction, genetic mutations, left ventricular apical aneurysms, myocardial fibrosis, and end stage disease.

Citing Articles

Coronary microvascular dysfunction, arrythmias, and sudden cardiac death: A literature review.

Dankar R, Wehbi J, Atasi M, Alam S, Refaat M Am Heart J Plus. 2024; 41:100389.

PMID: 38584700 PMC: 10998042. DOI: 10.1016/j.ahjo.2024.100389.

Arrhythmias and Hypertrophic Cardiomyopathy: Unravelling the Connection.

Aggarwal K, Boyapati S, Valecha J, Noor A, Kanwal F, Jain R Curr Cardiol Rev. 2024; 20(4):e240124226139.

PMID: 38279754 PMC: 11327833. DOI: 10.2174/011573403X279223231227111737.

The Microenvironment of the Pathogenesis of Cardiac Hypertrophy.

Bazgir F, Nau J, Nakhaei-Rad S, Amin E, Wolf M, Saucerman J Cells. 2023; 12(13).

PMID: 37443814 PMC: 10341218. DOI: 10.3390/cells12131780.

Treatment of myocardial interstitial fibrosis in pathological myocardial hypertrophy.

Zhu F, Li P, Sheng Y Front Pharmacol. 2022; 13:1004181.

PMID: 36249793 PMC: 9561344. DOI: 10.3389/fphar.2022.1004181.

Myocardial Interstitial Fibrosis in Nonischemic Heart Disease, Part 3/4: JACC Focus Seminar.

Diez J, Gonzalez A, Kovacic J J Am Coll Cardiol. 2020; 75(17):2204-2218.

PMID: 32354386 PMC: 7213023. DOI: 10.1016/j.jacc.2020.03.019.

References

Olivotto I, Gistri R, Petrone P, Pedemonte E, Vargiu D, Cecchi F . Maximum left ventricular thickness and risk of sudden death in patients with hypertrophic cardiomyopathy. J Am Coll Cardiol. 2003; 41(2):315-21. DOI: 10.1016/s0735-1097(02)02713-4. View

Fuster V, Ryden L, Cannom D, Crijns H, Curtis A, Ellenbogen K . ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for.... Circulation. 2006; 114(7):e257-354. DOI: 10.1161/CIRCULATIONAHA.106.177292. View

McKenna W, Oakley C, Krikler D, Goodwin J . Improved survival with amiodarone in patients with hypertrophic cardiomyopathy and ventricular tachycardia. Br Heart J. 1985; 53(4):412-6. PMC: 481782. DOI: 10.1136/hrt.53.4.412. View

Gaita F, Di Donna P, Olivotto I, Scaglione M, Ferrero I, Montefusco A . Usefulness and safety of transcatheter ablation of atrial fibrillation in patients with hypertrophic cardiomyopathy. Am J Cardiol. 2007; 99(11):1575-81. DOI: 10.1016/j.amjcard.2006.12.087. View

Maron B, Savage D, Wolfson J, Epstein S . Prognostic significance of 24 hour ambulatory electrocardiographic monitoring in patients with hypertrophic cardiomyopathy: a prospective study. Am J Cardiol. 1981; 48(2):252-7. DOI: 10.1016/0002-9149(81)90604-4. View

Monserrat L, Elliott P, Gimeno J, Sharma S, Penas-Lado M, McKenna W . Non-sustained ventricular tachycardia in hypertrophic cardiomyopathy: an independent marker of sudden death risk in young patients. J Am Coll Cardiol. 2003; 42(5):873-9. DOI: 10.1016/s0735-1097(03)00827-1. View

Chen M, McCarthy P, Lever H, Smedira N, Lytle B . Effectiveness of atrial fibrillation surgery in patients with hypertrophic cardiomyopathy. Am J Cardiol. 2004; 93(3):373-5. DOI: 10.1016/j.amjcard.2003.10.025. View

Maron B, Estes 3rd N, Maron M, Almquist A, Link M, Udelson J . Primary prevention of sudden death as a novel treatment strategy in hypertrophic cardiomyopathy. Circulation. 2003; 107(23):2872-5. DOI: 10.1161/01.CIR.0000072343.81530.75. View

Maron B, Shen W, Link M, EPSTEIN A, Almquist A, Daubert J . Efficacy of implantable cardioverter-defibrillators for the prevention of sudden death in patients with hypertrophic cardiomyopathy. N Engl J Med. 2000; 342(6):365-73. DOI: 10.1056/NEJM200002103420601. View

10.

Cecchi F, Olivotto I, Gistri R, Lorenzoni R, Chiriatti G, Camici P . Coronary microvascular dysfunction and prognosis in hypertrophic cardiomyopathy. N Engl J Med. 2003; 349(11):1027-35. DOI: 10.1056/NEJMoa025050. View

11.

Sadoul N, Prasad K, Elliott P, Bannerjee S, Frenneaux M, McKenna W . Prospective prognostic assessment of blood pressure response during exercise in patients with hypertrophic cardiomyopathy. Circulation. 1997; 96(9):2987-91. DOI: 10.1161/01.cir.96.9.2987. View

12.

Elliott P, Gimeno Blanes J, Mahon N, Poloniecki J, McKenna W . Relation between severity of left-ventricular hypertrophy and prognosis in patients with hypertrophic cardiomyopathy. Lancet. 2001; 357(9254):420-4. DOI: 10.1016/S0140-6736(00)04005-8. View

13.

Calkins H, Brugada J, Packer D, Cappato R, Chen S, Crijns H . HRS/EHRA/ECAS expert Consensus Statement on catheter and surgical ablation of atrial fibrillation: recommendations for personnel, policy, procedures and follow-up. A report of the Heart Rhythm Society (HRS) Task Force on catheter and surgical.... Heart Rhythm. 2007; 4(6):816-61. DOI: 10.1016/j.hrthm.2007.04.005. View

14.

Agarwal S, Tuzcu E, Desai M, Smedira N, Lever H, Lytle B . Updated meta-analysis of septal alcohol ablation versus myectomy for hypertrophic cardiomyopathy. J Am Coll Cardiol. 2010; 55(8):823-34. DOI: 10.1016/j.jacc.2009.09.047. View

15.

Maron B, Olivotto I, Spirito P, Casey S, BELLONE P, Gohman T . Epidemiology of hypertrophic cardiomyopathy-related death: revisited in a large non-referral-based patient population. Circulation. 2000; 102(8):858-64. DOI: 10.1161/01.cir.102.8.858. View

16.

Pelliccia A, Fagard R, Bjornstad H, Anastassakis A, Arbustini E, Assanelli D . Recommendations for competitive sports participation in athletes with cardiovascular disease: a consensus document from the Study Group of Sports Cardiology of the Working Group of Cardiac Rehabilitation and Exercise Physiology and the Working Group.... Eur Heart J. 2005; 26(14):1422-45. DOI: 10.1093/eurheartj/ehi325. View

17.

Maki S, Ikeda H, Muro A, Yoshida N, Shibata A, Koga Y . Predictors of sudden cardiac death in hypertrophic cardiomyopathy. Am J Cardiol. 1998; 82(6):774-8. DOI: 10.1016/s0002-9149(98)00455-x. View

18.

Matsui Y, Fukada Y, Imai T, Naito Y, Sasaki S . Combined cox maze procedure, septal myectomy, and mitral valve replacement for severe hypertrophic obstructive cardiomyopathy complicated by chronic atrial fibrillation. Ann Thorac Cardiovasc Surg. 2003; 9(5):323-5. View

19.

Talreja D, Nishimura R, Edwards W, Valeti U, Ommen S, Tajik A . Alcohol septal ablation versus surgical septal myectomy: comparison of effects on atrioventricular conduction tissue. J Am Coll Cardiol. 2004; 44(12):2329-32. DOI: 10.1016/j.jacc.2004.09.036. View

20.

Spirito P, BELLONE P, Harris K, Bernabo P, Bruzzi P, Maron B . Magnitude of left ventricular hypertrophy and risk of sudden death in hypertrophic cardiomyopathy. N Engl J Med. 2000; 342(24):1778-85. DOI: 10.1056/NEJM200006153422403. View